Improving Pharmacokinetics of Peptides Using Phage Display

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Discovery

Background:

• Phage display is a powerful technique for identifying peptides that bind to disease biomarkers.
• While affinity selection (biopanning) is cost-effective, the resulting peptides often have suboptimal pharmacokinetic properties.
• Peptide pharmacokinetics significantly impact their efficacy in targeting biomarkers within a biological system.

Purpose of the Study:

• To highlight the importance of experimental conditions in phage display biopanning.
• To emphasize the need to consider pharmacokinetics alongside binding affinity during peptide selection.
• To guide strategies for developing peptides and peptide-conjugated nanoparticles with improved in vivo targeting capabilities.

Main Methods:

• Utilizing phage display technology for peptide library screening.
• Employing affinity selection techniques, including in vitro, in situ, and in vivo biopanning.
• Analyzing the influence of different biopanning strategies on peptide and nanoparticle biodistribution and clearance.

Main Results:

• Peptide affinity is readily optimized, but pharmacokinetic properties often require further refinement.
• In vivo biopanning strategies, or combinations thereof, demonstrably influence peptide and nanoparticle biodistribution and clearance.
• Differences in physiochemical properties (peptides) and size/shape (nanoparticles) affect absorption and distribution.

Conclusions:

• Careful selection of biopanning conditions is essential for generating peptides with both high affinity and desirable pharmacokinetics.
• In vivo biopanning approaches can be leveraged to optimize peptide and peptide-nanoparticle biodistribution for effective biomarker targeting.
• Integrating pharmacokinetic considerations into biopanning strategies is critical for the successful development of targeted therapeutics.